Long-term safety and efficacy of tafamidis for the treatment of hereditary transthyretin amyloid polyneuropathy: results up to 6 years.
about
Transthyretin familial amyloid polyneuropathy: an update.Tafamidis delays neurological progression comparably across Val30Met and non-Val30Met genotypes in transthyretin familial amyloid polyneuropathy.Understanding the Disease Course and Therapeutic Benefit of Tafamidis Across Real-World Studies of Hereditary Transthyretin Amyloidosis with Polyneuropathy: A Proof of Concept for Integrative Data Analytic Approaches.Amyloid assembly and disassembly
P2860
Long-term safety and efficacy of tafamidis for the treatment of hereditary transthyretin amyloid polyneuropathy: results up to 6 years.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh
2017年學術文章
@zh-hant
name
Long-term safety and efficacy ...... opathy: results up to 6 years.
@en
type
label
Long-term safety and efficacy ...... opathy: results up to 6 years.
@en
prefLabel
Long-term safety and efficacy ...... opathy: results up to 6 years.
@en
P2093
P2860
P1433
P1476
Long-term safety and efficacy ...... opathy: results up to 6 years.
@en
P2093
Leslie Amass
Marla B Sultan
Michelle Stewart
P2860
P304
P356
10.1080/13506129.2017.1357545
P577
2017-07-31T00:00:00Z